Neuronetics (STIM) Q2 Loss Wider Than Expected, Revenues Fall Y/YZacks Investment Research • 08/13/24
Noninvasive Treatment Provider Neuronetics Agrees To Merge With Canadian Firm Greenbrook TMS; Reports Q2 Earnings And Guidance Below ExpectationsBenzinga • 08/12/24
Neuronetics Reports Record Second Quarter 2024 Financial and Operating ResultsGlobeNewsWire • 08/12/24
NeuroStar Partners With This Is My Brave to Recognize Teen Mental Health MonthGlobeNewsWire • 08/01/24
Neuronetics Announces the Closing of up to $90 Million Senior Secured Credit Facility with Perceptive AdvisorsGlobeNewsWire • 07/30/24
Neuronetics to Report Second Quarter 2024 Financial and Operating Results and Host Conference CallGlobeNewsWire • 07/29/24
BlueCross BlueShield MI and Cambia Health Solutions Expand TMS Access for Depressed AdolescentsGlobeNewsWire • 07/10/24
NeuroStar Showcases Cutting-Edge Research at Clinical TMS Society Annual MeetingGlobeNewsWire • 06/13/24
Neuronetics to Present at the William Blair 44th Annual Growth Stock ConferenceGlobeNewsWire • 05/23/24
Humana Is First Commercial Payer to Address TMS Therapy Coverage for AdolescentsGlobeNewsWire • 05/15/24
Neuronetics Reports Record First Quarter 2024 Financial and Operating ResultsGlobeNewsWire • 05/07/24
NeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness MonthGlobeNewsWire • 05/01/24
Neuronetics to Report First Quarter 2024 Financial and Operating Results and Host Conference CallGlobeNewsWire • 04/23/24
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is VitalGlobeNewsWire • 04/10/24
NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with DepressionGlobeNewsWire • 03/25/24